middle.news
Prescient funds PTX-100 beyond key December review
10:03am on Wednesday 23rd of September, 2026 AEST
•
Biotechnology
Read Story
Prescient funds PTX-100 beyond key December review
10:03am on Wednesday 23rd of September, 2026 AEST
Key Points
Approximately $4.8 million raised through the Share Purchase Plan
Approximately $1.2 million secured through a shortfall placement
Funding extends PTX-100 development beyond the December 2026 Dose Optimisation Committee review
Phase 2 study has enrolled 20 of 40 planned evaluable patients
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE